Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.64 |
| ▸ | NPC1 | O15118 | 2/20 | 0.64 |
| ▸ | RAB9A | P51151 | 2/20 | 0.64 |
| ▸ | POLB | P06746 | 1/20 | 0.64 |
| ▸ | HTT | P42858 | 1/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.64 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.58 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.58 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.58 |
| ▸ | KCNK3 | O14649 | 10/20 | 0.52 |
| ▸ | KCNK9 | Q9NPC2 | 10/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13341898 | 0.89 | NPC1 (0.54) | KDM4ENPC1RAB9APOLBHTT | |
| SCHEMBL5566700 | 0.86 | ALDH1A1 (0.65) | KDM4ENPC1RAB9APOLBHTT | |
| SCHEMBL13368336 | 0.83 | ALDH1A1 (0.63) | KDM4EHTTGABRB2SLC2A1 | |
| Hydrochloric Acid SCHEMBL1430093 | 0.82 | KDM4E (0.69) | KDM4ENPC1RAB9APOLBHTT | |
| SCHEMBL1691661 | 0.82 | KDM4E (0.69) | KDM4ENPC1RAB9APOLBHTT | |
| SCHEMBL1431043 | 0.82 | KDM4E (0.69) | KDM4ENPC1RAB9APOLBHTT | |
| SCHEMBL8208 | 0.81 | KDM4E (0.64) | KDM4ENPC1RAB9APOLBHTT | |
| SCHEMBL18963197 | 0.79 | KDM4E (0.75) | KDM4EGAASLC2A1KCNK3KCNK9 | |
| SCHEMBL1430465 | 0.79 | NPC1 (0.74) | KDM4ENPC1RAB9APOLBHTT | |
| SCHEMBL1430221 | 0.78 | KDM4E (0.67) | KDM4ENPC1RAB9APOLBHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7723324-B2 | Imidazo[1,2-A]pyridine anxiolytics | SEPRACOR, INC. (US) | 2010-05-25 | — | — | US | disclosed |
| US-20080096867-A1 | Imidazo[1,2-A] Pyridine Anxiolytics | SEPRACOR INC. (US) | 2008-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080096867-A1 | Imidazo[1,2-A] Pyridine Anxiolytics | MTNR1B, ADORA2B, ADRA2B | KDM4E 796/4885NPC1 1038/4885RAB9A 995/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.